Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.68 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MERTK | Q12866 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218492 | 1.00 | GRM5 (0.68) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL23425256 | 1.00 | GRM5 (0.68) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL29590900 | 1.00 | GRM5 (0.68) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL30043283 | 0.91 | GRM5 (0.61) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL30043552 | 0.91 | GRM5 (0.61) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL30044693 | 0.91 | GRM5 (0.61) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL18025266 | 0.90 | GRM5 (0.59) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL26923664 | 0.90 | GRM5 (0.59) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL30044931 | 0.88 | GRM5 (0.65) | GRM5GAACYP1A2SMYD3CRBN | |
| SCHEMBL30975217 | 0.88 | GRM5 (0.65) | GRM5GAACYP1A2SMYD3CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927091-B2 | Continuous carbonylation processes | NOVOMER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10910642-B1 | Redox flow battery having ligand-metal complex | TRIAD NATIONAL SECURITY, LLC (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200331878-A1 | CONTINUOUS CARBONYLATION PROCESSES | NOVOMER, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10738022-B2 | Continuous carbonylation processes | NOVOMER, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190345125-A1 | CONTINUOUS CARBONYLATION PROCESSES | NOVOMER, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-10221150-B2 | Continuous carbonylation processes | NOVOMER, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180030015-A1 | CONTINUOUS CARBONYLATION PROCESSES | NOVOMER, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-8383673-B2 | Nitridoosmium(VI) complexes for treatment of cancer | CITY UNIVERSITY OF HONG KONG (HK) | 2013-02-26 | — | — | US | disclosed |
| US-8383673-B2 | Nitridoosmium(VI) complexes for treatment of cancer | CITY UNIVERSITY OF HONG KONG (HK) | 2013-02-26 | — | — | US | disclosed |
| US-20110230456-A1 | Nitridoosmium(VI) Complexes for Treatment of Cancer | THE CITY UNIVERSITY OF HONG KONG (HK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230456-A1 | Nitridoosmium(VI) Complexes for Treatment of Cancer | THE CITY UNIVERSITY OF HONG KONG (HK) | 2011-09-22 | — | — | US | disclosed |
| US-6506908-B2 | From bicyclo(3.1.0)hexabe; decyclization; decarboxylation | MERCK & CO., INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020016492-A1 | Process for preparing 3-hydroxymethyl-4-(aryl or heterocyclic)-cyclopentanones | MERCK SHARP & DOHME CORP. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030015-A1 | CONTINUOUS CARBONYLATION PROCESSES | CBR1, CBR3, CYC1 | GRM5 2416/4885GAA 2613/4885CYP1A2 17/4885 |
| US-20190345125-A1 | CONTINUOUS CARBONYLATION PROCESSES | CBR1, CBR3, CYC1 | GRM5 2416/4885GAA 2613/4885CYP1A2 17/4885 |
| US-20110230456-A1 | Nitridoosmium(VI) Complexes for Treatment of Cancer | NPM1, IDH2, MT-ND5 | GRM5 243/4885GAA 2583/4885CYP1A2 1379/4885 |
| US-10221150-B2 | Continuous carbonylation processes | CBR1, CBR3, CYC1 | GRM5 2416/4885GAA 2613/4885CYP1A2 17/4885 |
| US-20200331878-A1 | CONTINUOUS CARBONYLATION PROCESSES | CBR1, CBR3, CYC1 | GRM5 2416/4885GAA 2613/4885CYP1A2 17/4885 |
| US-20020016492-A1 | Process for preparing 3-hydroxymethyl-4-(aryl or heterocyclic)-cyclopentanones | CCR1, CCR5, CCR6 | GRM5 877/4885GAA 3331/4885CYP1A2 1129/4885 |
| US-10738022-B2 | Continuous carbonylation processes | CBR1, CBR3, CYC1 | GRM5 2416/4885GAA 2613/4885CYP1A2 17/4885 |
| US-10927091-B2 | Continuous carbonylation processes | CBR1, CBR3, CYC1 | GRM5 2416/4885GAA 2613/4885CYP1A2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.